Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
Sponsor: Bayer
Terminated
This trial was terminated. No reason was provided.
A PHASE3 clinical study on Blood Loss, Surgical and Postoperative Hemorrhage, this trial is terminated or withdrawn. The trial is conducted by Bayer and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Berlin, Germany , Karlsbad, Germany , Madrid, Spain , Montreal, Canada , Münster, Germany , Neustadt, Germany , Oshawa, Canada , Pamplona, Spain , Valencia, Spain and 1 more location